Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned? - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Journal of Inherited Metabolic Disease Année : 2015

Dates et versions

inserm-02894834 , version 1 (09-07-2020)
inserm-02894834 , version 2 (09-07-2020)

Identifiants

Citer

Jean Bastin, Jean-Paul Bonnefont, Fatima Djouadi, Jean-Louis Bresson. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?. Journal of Inherited Metabolic Disease, 2015, 38 (2), pp.371-372. ⟨10.1007/s10545-014-9775-7⟩. ⟨inserm-02894834v1⟩
93 Consultations
166 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More